8-K: Certara Reports Q1 2026 Results, Divests Business

Certara announced its first quarter 2026 financial results, reporting a 1% revenue increase and a net loss, while also completing the divestiture of its medical writing business.

Summary

• Certara reported first quarter 2026 revenue of $106.9 million, a 1% increase from $106.0 million in the prior year's quarter.
• Software revenue grew 7% to $49.7 million, while services revenue decreased 4% to $57.2 million.
• The company reported a net loss of $8.8 million for the quarter, a significant decrease from a net income of $4.7 million in Q1 2025.
• Adjusted EBITDA decreased by 9% to $31.7 million from $34.8 million in Q1 2025.
• Certara completed the sale of its global medical writing and related regulatory services business to Veristat, LLC on May 8, 2026, for $85.0 million in cash, plus an additional $15 million in escrow and up to $35 million in contingent consideration.
• The company updated its full-year 2026 revenue guidance to $395 million - $405 million, reflecting the divestiture, with expected growth of 0%-4% excluding the divested business.
• Full-year 2026 Adjusted EBITDA margin is projected to be 30%-32%, and adjusted diluted earnings per share are expected to be between $0.35 - $0.41.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed signal; while the divestiture is a positive strategic move, the reported decline in profitability and mixed revenue performance in the current quarter present significant headwinds.

Positives

• Software revenue showed strong growth of 7% year-over-year, indicating positive performance in this segment.
• Software bookings increased by 20% year-over-year, signaling strong future demand for software products.
• The divestiture of the medical writing business is expected to sharpen execution and position Certara for long-term growth.
• The company is accelerating its enterprise-wide AI program.

Negatives

• Net loss for the quarter was $8.8 million, a significant decrease of 285% compared to a net income of $4.7 million in Q1 2025.
• Adjusted EBITDA decreased by 9% to $31.7 million from $34.8 million in Q1 2025.
• Services revenue decreased by 4% year-over-year.
• Total bookings decreased by 2% year-over-year, driven by a 14% decrease in services bookings.

Risks

• The company faces risks related to the integration and performance of its remaining business segments post-divestiture.
• Execution and go-to-market challenges in the services segment are expected to be resolved in the second half of the year, implying ongoing near-term performance issues.
• The company's ability to compete within its market and adapt to changes in research and development spending trends.
• Potential for disruption from the divestiture transaction impacting business and operational relationships.
• Risks associated with the implementation, use, and development of artificial intelligence and machine learning in its products and services.

Future Outlook

Full-year 2026 revenue is projected to be between $395 million and $405 million, including approximately $18 million from the divested business. Excluding the divested business, revenue growth is expected to be between 0% and 4%. Full-year Adjusted EBITDA margin is anticipated to be 30%-32%. Adjusted diluted earnings per share for the full year are forecasted to be in the range of $0.35 to $0.41.

Management Comments

• "I am pleased with the progress we made in my first quarter at Certara," said Jon Resnick, Chief Executive Officer. "We are taking decisive steps to sharpen our execution and position Certara for long-term growth, including divesting our Medical Writing business, reorganizing around two focused growth areas, and accelerating our enterprise-wide AI program. Together, these actions strengthen our ability to transform drug development and deliver greater value to our customers and shareholders."
• "Our first quarter performance reflects improvement in software, which came in above plan across key metrics. Services performance was mixed, reflecting execution and go-to-market challenges that we expect to resolve during the second half of the year," said John Gallagher, Chief Financial Officer. "With the divestiture of our Regulatory and Medical Writing Business, we expect the mix of software and services revenue to be approximately even. Our updated 2026 guidance reflects the impact of the divestiture during the second quarter, and revenue growth expectations of 0% - 4% excluding the Regulatory and Medical Writing Business."

Industry Context

StockSavvy.ai notes that Certara's strategic shift towards a more focused business model, emphasizing biosimulation software and services, aligns with broader industry trends of specialization and leveraging AI in drug development. The divestiture of a non-core service business is a common strategy for companies seeking to streamline operations and enhance shareholder value.

Stakeholder Impact

• Shareholders: The divestiture aims to improve long-term value, but the current financial performance and updated guidance may lead to short-term stock price volatility.
• Employees: Reorganization around two focused growth areas may lead to changes in team structures and responsibilities.
• Customers: The company aims to deliver greater value to customers through its focused strategy and AI acceleration.

Next Steps

• Resolve execution and go-to-market challenges in the services segment during the second half of the year.
• Continue to accelerate the enterprise-wide AI program.
• Focus on growth in two reorganized areas of the business.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation with the divestiture of a business segment. While this move is intended to improve focus and long-term growth, the current quarter's financial results show a decline in profitability and mixed revenue performance. The updated guidance provides some clarity, but the execution risk associated with resolving services challenges and integrating the new structure warrants a cautious 'hold' until performance trends stabilize and the benefits of the strategic shift become more evident.

Keywords

Certara, 8-K, Financial Results, Q1 2026, Divestiture, Biosimulation, Drug Development, Regulatory Writing